AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 414402 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 31145383 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-body resistance exercise (FB)
Number of subjects: 12
Study 31145383 — intervention group
Group type: COMPARATOR
Intervention: Upper body resistance exercise (UB)
Number of subjects: 12
Study 31145383 — intervention group
Group type: COMPARATOR
Intervention: Lower body resistance exercise (LB)
Number of subjects: 12
Study 31392725 — intervention group
Group type: EXPERIMENTAL
Intervention: Seprafilm (two sheets inserted under a midline incision)
Number of subjects: 345
Study 31392725 — intervention group
Group type: COMPARATOR
Intervention: Control group (no seprafilm)
Number of subjects: 345
Study 31392725 — intervention group
Group type: EXPERIMENTAL
Intervention: Seprafilm
Number of subjects: 345
Study 31392725 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 345
Study 27919627 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed followed by erlotinib (150 mg orally once daily on days 2-17)
Number of subjects: 83
Study 27919627 — intervention group
Group type: COMPARATOR
Intervention: Pemetrexed alone (500 mg/m2 intravenously on day 1)
Number of subjects: 83
Study 27919627 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed followed by erlotinib
Number of subjects: 83
Study 27919627 — intervention group
Group type: COMPARATOR
Intervention: Pemetrexed alone
Number of subjects: 83
Study 26033398 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel treatment without abciximab
Number of subjects: 125
Study 26033398 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel treatment with abciximab
Number of subjects: 125
Study 26033398 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with HRPR
Number of subjects: 125
Study 26033398 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with low residual platelet reactivity (LRPR)
Number of subjects: 125
Study 23475636 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertuzumab plus trastuzumab plus docetaxel
Number of subjects: 0
Study 23475636 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus trastuzumab plus docetaxel
Number of subjects: 0
Study 22176931 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 899
Study 19692796 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbate treatment (intravenous vitamin C)
Number of subjects: 38
Study 19692796 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (normal saline infusion)
Number of subjects: 38
Study 16476851 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 16
Study 16476851 — intervention group
Group type: COMPARATOR
Intervention: Control (unchanged therapy)
Number of subjects: 16
Study 15379272 — intervention group
Group type: EXPERIMENTAL
Intervention: rhTPO 1.0 microg/(kg x d) administered subcutaneously for up to 14 days after chemotherapy
Number of subjects: 154
Study 11246381 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketorolac
Number of subjects: 30
Study 11246381 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular bupivacaine
Number of subjects: 30
Study 11246381 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 8992351 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive treatment to lower LDL cholesterol levels (with lovastatin and, if needed, cholestyramine)
Number of subjects: 1351
Study 8992351 — intervention group
Group type: COMPARATOR
Intervention: Moderate treatment to lower LDL cholesterol levels
Number of subjects: 1351
Study 8992351 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive treatment to lower LDL cholesterol levels
Number of subjects: 1351
Study 8992351 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin treatment
Number of subjects: 1351
Study 8992351 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 1351
Study 8256082 — intervention group
Group type: EXPERIMENTAL
Intervention: Glypressin (intravenous)
Number of subjects: 0
Study 8256082 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3547298 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffy coat transfusions (15 mL/kg)
Number of subjects: 20
Study 3547298 — intervention group
Group type: COMPARATOR
Intervention: Plasma and blood products
Number of subjects: 20
Study 3547298 — intervention group
Group type: COMPARATOR
Intervention: Observation (no intervention)
Number of subjects: 20
Study 31978565 — intervention group
Group type: EXPERIMENTAL
Intervention: PDT + SRP
Number of subjects: 73
Study 31978565 — intervention group
Group type: EXPERIMENTAL
Intervention: SP + SRP
Number of subjects: 73
Study 31978565 — intervention group
Group type: COMPARATOR
Intervention: SRP alone
Number of subjects: 73
Study 30808316 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% Povidone-Iodine (PI)
Number of subjects: 21
Study 30808316 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% Povidone-Iodine (PI)
Number of subjects: 21
Study 30808316 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% Povidone-Iodine (PI)
Number of subjects: 21
Study 30808316 — intervention group
Group type: COMPARATOR
Intervention: Control (no pre-application)
Number of subjects: 21
Study 27650536 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetagastrodin
Number of subjects: 92
Study 27650536 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 92
Study 24998617 — intervention group
Group type: EXPERIMENTAL
Intervention: LI-BFR (low-intensity with blood flow restriction)
Number of subjects: 17
Study 24998617 — intervention group
Group type: COMPARATOR
Intervention: HI (high-intensity resistance exercise)
Number of subjects: 17
Study 23163616 — intervention group
Group type: EXPERIMENTAL
Intervention: Larazotide acetate 1 mg
Number of subjects: 184
Study 23163616 — intervention group
Group type: EXPERIMENTAL
Intervention: Larazotide acetate 4 mg
Number of subjects: 184
Study 23163616 — intervention group
Group type: EXPERIMENTAL
Intervention: Larazotide acetate 8 mg
Number of subjects: 184
Study 23163616 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 184
Study 21994147 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol nasal irrigation
Number of subjects: 20
Study 21994147 — intervention group
Group type: COMPARATOR
Intervention: Saline nasal irrigation
Number of subjects: 20
Study 18474495 — intervention group
Group type: EXPERIMENTAL
Intervention: EFV + TDF/FTC
Number of subjects: 402
Study 16566674 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupressure plus Internet-assisted smoking cessation program
Number of subjects: 2
Study 16566674 — intervention group
Group type: COMPARATOR
Intervention: Auricular acupressure only
Number of subjects: 2
Study 15198998 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy
Number of subjects: 120
Study 15198998 — intervention group
Group type: COMPARATOR
Intervention: Body conditioning (placebo control)
Number of subjects: 120
Study 15198998 — intervention group
Group type: COMPARATOR
Intervention: Normal care control group
Number of subjects: 120
Study 11390253 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha‐methyl‐para‐tyrosine (AMPT) 1-g doses
Number of subjects: 9
Study 11390253 — intervention group
Group type: COMPARATOR
Intervention: promethazine (active placebo) 50-mg doses
Number of subjects: 9
Study 9415535 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous methylprednisolone (1000 mg per day) for five days
Number of subjects: 44
Study 9415535 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 8301876 — intervention group
Group type: EXPERIMENTAL
Intervention: TJ-960 (7.5 g per day for 8 weeks)
Number of subjects: 26
Study 8301876 — intervention group
Group type: EXPERIMENTAL
Intervention: TJ-960
Number of subjects: 26
Study 8301876 — intervention group
Group type: COMPARATOR
Intervention: Control group (no change in regimen)
Number of subjects: 26
Study 3771949 — intervention group
Group type: EXPERIMENTAL
Intervention: Uniphyl, 800 mg four times a day (qd)
Number of subjects: 28
Study 3771949 — intervention group
Group type: EXPERIMENTAL
Intervention: metered-dose albuterol, active, 180 micrograms four times a day (qid)
Number of subjects: 28
Study 3771949 — intervention group
Group type: EXPERIMENTAL
Intervention: Uniphyl, 400 mg twice daily
Number of subjects: 28
Study 3771949 — intervention group
Group type: COMPARATOR
Intervention: Uniphyl, 800 mg qd; placebo, two puffs qid
Number of subjects: 28
Study 3771949 — intervention group
Group type: COMPARATOR
Intervention: Uniphyl, 400 mg twice daily; placebo, two puffs qid
Number of subjects: 28
Study 28933653 — intervention group
Group type: EXPERIMENTAL
Intervention: Navigated women (741)
Number of subjects: 2536
Study 28933653 — intervention group
Group type: COMPARATOR
Intervention: Non-navigated women (1,795)
Number of subjects: 2536
Study 27393499 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib with gemcitabine/platinum
Number of subjects: 256
Study 27393499 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 256
Study 27393499 — intervention group
Group type: COMPARATOR
Intervention: Placebo with gemcitabine/platinum
Number of subjects: 256
Study 25588394 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg 1 time per day for 3 days
Number of subjects: 60
Study 25588394 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg 1 time per day for 7 days followed by 500 mg 1 time per week for 12 weeks
Number of subjects: 60
Study 25588394 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term adjunctive azithromycin
Number of subjects: 60
Study 22447637 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief interpersonal psychotherapy (IPT-B)
Number of subjects: 53
Study 22447637 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 53
Study 19891803 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar-I disorder (BP-I) probands
Number of subjects: 487
Study 19891803 — intervention group
Group type: COMPARATOR
Intervention: Attention deficit hyperactivity disorder (ADHD) probands
Number of subjects: 487
Study 19891803 — intervention group
Group type: COMPARATOR
Intervention: Healthy control probands
Number of subjects: 487
Study 18217152 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day for six months
Number of subjects: 100
Study 18217152 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical treatment (control group)
Number of subjects: 100
Study 11332168 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking mothers
Number of subjects: 203
Study 9568663 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic sutured repair
Number of subjects: 22
Study 9568663 — intervention group
Group type: COMPARATOR
Intervention: Open omental repair
Number of subjects: 22
Study 9568663 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 22
Study 7871647 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive myopia
Number of subjects: 248
Study 7871647 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic retinopathy
Number of subjects: 248
Study 7871647 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-angle glaucoma
Number of subjects: 248
Study 7871647 — intervention group
Group type: COMPARATOR
Intervention: Control group (without ocular diseases)
Number of subjects: 248
Study 2901125 — intervention group
Group type: COMPARATOR
Intervention: Flupentixol 1 mg
Number of subjects: 12
Study 2901125 — intervention group
Group type: COMPARATOR
Intervention: Flupentixol 2 mg
Number of subjects: 12
Study 2901125 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam 2.5 mg
Number of subjects: 12
Study 2901125 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 15 mg
Number of subjects: 12
Study 2901125 — intervention group
Group type: EXPERIMENTAL
Intervention: Flupentixol 1 mg + Diazepam 15 mg
Number of subjects: 12
Study 2901125 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31032524 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic-Controlled Capsule Endoscopy (MCE)
Number of subjects: 98
Study 31032524 — intervention group
Group type: COMPARATOR
Intervention: Middle-aged group (control)
Number of subjects: 98
Study 29091217 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted lopinavir (400/100 mg)
Number of subjects: 157
Study 29091217 — intervention group
Group type: COMPARATOR
Intervention: Cobicistat-boosted elvitegravir (150/150 mg)
Number of subjects: 157
Study 29091217 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (both groups)
Number of subjects: 157
Study 29091217 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified ITT analysis (lopinavir/ritonavir)
Number of subjects: 157
Study 29091217 — intervention group
Group type: COMPARATOR
Intervention: Modified ITT analysis (elvitegravir/cobicistat)
Number of subjects: 157
Study 29091217 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall adherence
Number of subjects: 157
Study 29091217 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 157
Study 29091217 — intervention group
Group type: COMPARATOR
Intervention: Seroconversion
Number of subjects: 157
Study 26863333 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin vaginal inserts (dinoprostone 10 mg, misoprostol 50 mcg or 100 mcg)
Number of subjects: 1308
Study 23333174 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Shoulder Replacement (TSR)
Number of subjects: 33
Study 23333174 — intervention group
Group type: COMPARATOR
Intervention: Hemiarthroplasty (HA)
Number of subjects: 33
Study 21467183 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcorneal electrical stimulation (TES) at 150% of individual electrical phosphene threshold (EPT)
Number of subjects: 24
Study 21467183 — intervention group
Group type: COMPARATOR
Intervention: Transcorneal electrical stimulation (TES) at 66% of individual electrical phosphene threshold (EPT)
Number of subjects: 24
Study 21467183 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 24
Study 18419630 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 100 mg oral suspension once daily
Number of subjects: 270
Study 18419630 — intervention group
Group type: COMPARATOR
Intervention: Placebo oral suspension once daily
Number of subjects: 270
Study 16864931 — intervention group
Group type: EXPERIMENTAL
Intervention: ARB plus spironolactone (SPRL) 25 mg/day for 6 months
Number of subjects: 70
Study 16864931 — intervention group
Group type: COMPARATOR
Intervention: ARB (candesartan 8 mg/day) for 1 year
Number of subjects: 70
Study 12620527 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fat diet (15% of energy from fat with maintenance of energy intake)
Number of subjects: 41
Study 12620527 — intervention group
Group type: EXPERIMENTAL
Intervention: Low energy diet (25% energy reduction with maintenance of percentage of energy from fat)
Number of subjects: 41
Study 12620527 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined low fat and low energy diet
Number of subjects: 41
Study 12620527 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention (control group)
Number of subjects: 41
Study 10846272 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance telephone prompt
Number of subjects: 179
Study 10846272 — intervention group
Group type: COMPARATOR
Intervention: Advance letter prompt only
Number of subjects: 179
Study 9335081 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (150 micrograms)
Number of subjects: 0
Study 9335081 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8227490 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 50
Study 8227490 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 30325776 — intervention group
Group type: EXPERIMENTAL
Intervention: Cash transfers (∼$11 per month for ≤6 months, conditional on visit attendance)
Number of subjects: 805
Study 30325776 — intervention group
Group type: EXPERIMENTAL
Intervention: Food transfers (∼$11 per month for ≤6 months, conditional on visit attendance)
Number of subjects: 805
Study 30325776 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care (SOC) services
Number of subjects: 805
Study 30573551 — intervention group
Group type: EXPERIMENTAL
Intervention: Strangulation
Number of subjects: 175
Study 30573551 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support
Number of subjects: 175
Study 26983672 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (Arm A)
Number of subjects: 60
Study 26983672 — intervention group
Group type: COMPARATOR
Intervention: Passive physical therapy (Arm B)
Number of subjects: 60
Study 24963567 — intervention group
Group type: EXPERIMENTAL
Intervention: Insertable cardiac monitor (ICM)
Number of subjects: 441
Study 24963567 — intervention group
Group type: COMPARATOR
Intervention: Conventional follow-up (control)
Number of subjects: 441
Study 22854050 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated HER-receptors (pHER1, pHER2, pHER3)
Number of subjects: 1062
Study 22854050 — intervention group
Group type: EXPERIMENTAL
Intervention: HER2
Number of subjects: 1062
Study 22854050 — intervention group
Group type: EXPERIMENTAL
Intervention: Other HER-family members
Number of subjects: 1062
Study 20669668 — intervention group
Group type: EXPERIMENTAL
Intervention: Ningxintong Granule (NXTG) combined with Western medical conventional treatment
Number of subjects: 76
Study 20669668 — intervention group
Group type: COMPARATOR
Intervention: Western medical conventional treatment alone
Number of subjects: 76
Study 18544991 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel given on a 3-week schedule
Number of subjects: 0
Study 16723056 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive end-expiratory pressure at 10 mbar
Number of subjects: 72
Study 16723056 — intervention group
Group type: COMPARATOR
Intervention: Positive end-expiratory pressure at 0 mbar
Number of subjects: 72
Study 16723056 — intervention group
Group type: COMPARATOR
Intervention: Positive end-expiratory pressure at 5 mbar
Number of subjects: 72
Study 12483420 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial imaging with [N-methyl (11)C]meta-hydroxyephedrine ((11)C-HED) and positron emission tomography (PET)
Number of subjects: 7
Study 10984081 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg sublingual)
Number of subjects: 19
Study 10984081 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (90 mg single dose)
Number of subjects: 19
Study 10984081 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 8571990 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbilical artery Doppler velocimetry
Number of subjects: 0
Study 8571990 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 1281046 — intervention group
Group type: EXPERIMENTAL
Intervention: EDX-L (epirubicin-lipiodol emulsion)
Number of subjects: 18
Study 1281046 — intervention group
Group type: EXPERIMENTAL
Intervention: EDX-L followed by GS (gelatin sponge)
Number of subjects: 18
Study 1281046 — intervention group
Group type: COMPARATOR
Intervention: DX-L (doxorubicin-lipiodol emulsion)
Number of subjects: 18
Study 1281046 — intervention group
Group type: COMPARATOR
Intervention: GS (gelatin sponge only)
Number of subjects: 18
Study 3969014 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin alone
Number of subjects: 0
Study 3969014 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin alternating with growth hormone (combined treatment)
Number of subjects: 0
Study 3969014 — intervention group
Group type: COMPARATOR
Intervention: Control group (Calcitonin)
Number of subjects: 0
Study 30040016 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 weeks of textured balance board training (1 minute daily)
Number of subjects: 42
Study 30040016 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 weeks of textured balance board training (1 minute daily)
Number of subjects: 42
Study 30040016 — intervention group
Group type: COMPARATOR
Intervention: Baseline scores for dancers with PAS
Number of subjects: 42
Study 30040016 — intervention group
Group type: COMPARATOR
Intervention: Comparison between dancers with and without chronic ankle instability
Number of subjects: 42
Study 29489681 — intervention group
Group type: EXPERIMENTAL
Intervention: PO-based administration set
Number of subjects: 9
Study 29489681 — intervention group
Group type: COMPARATOR
Intervention: PU-based administration set
Number of subjects: 9
Study 29489681 — intervention group
Group type: COMPARATOR
Intervention: PVC-based administration set
Number of subjects: 9
Study 27103982 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) at a target dose of 60 mg/kg/day in three divided doses
Number of subjects: 31
Study 27103982 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 27103982 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 31
Study 27103982 — intervention group
Group type: COMPARATOR
Intervention: N-acetylcysteine (NAC) and Placebo
Number of subjects: 31
Study 24453077 — intervention group
Group type: EXPERIMENTAL
Intervention: RBC EPA + DHA (omega‐3 index)
Number of subjects: 1111
Study 24453077 — intervention group
Group type: EXPERIMENTAL
Intervention: RBC DHA
Number of subjects: 1111
Study 24453077 — intervention group
Group type: EXPERIMENTAL
Intervention: RBC EPA
Number of subjects: 1111
Study 23342619 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoflavin (in infusion, then oral administration)
Number of subjects: 60
Study 23342619 — intervention group
Group type: COMPARATOR
Intervention: Baseline therapy (alpha1‐adrenoblockers, non‐specific anti‐inflammatory drugs, digital prostate massage and vacuum phallostimulation)
Number of subjects: 60
Study 20175053 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate plus half saline
Number of subjects: 72
Study 20175053 — intervention group
Group type: COMPARATOR
Intervention: Half saline alone
Number of subjects: 72
Study 17703122 — intervention group
Group type: EXPERIMENTAL
Intervention: In-home psychotherapy for depressive symptoms; details on dosage and duration not specified.
Number of subjects: 0
Study 16325694 — intervention group
Group type: EXPERIMENTAL
Intervention: Bypass surgery
Number of subjects: 452
Study 16325694 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon angioplasty
Number of subjects: 452
Study 16325694 — intervention group
Group type: COMPARATOR
Intervention: Surgery-first strategy
Number of subjects: 452